Not sure why no specific mention in recent announcements but I suspect they want to keep the messaging on Remplir, especially in the U.S., and Striate+ information — where for both products we are gaining more approvals and sales traction. There’s just so much going on in the company.
The last update on SmrtGraft was 26 Feb, just 7 weeks ago, where the company was expecting a CY2025 launch in Australia. Not long to wait with TGA’s statutory deadline looming if all is going smoothly behind the scenes. I’m quietly confident given SmrtGraft’s use in the SAS, and the clinical study data submitted to the TGA demonstrated a 100% success rate for RC tendon repair and no subsequent revision surgery for a re-tear being required.
OCC Price at posting:
$1.36 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)